FR07C0001I2 - - Google Patents

Info

Publication number
FR07C0001I2
FR07C0001I2 FR07C0001C FR07C0001C FR07C0001I2 FR 07C0001 I2 FR07C0001 I2 FR 07C0001I2 FR 07C0001 C FR07C0001 C FR 07C0001C FR 07C0001 C FR07C0001 C FR 07C0001C FR 07C0001 I2 FR07C0001 I2 FR 07C0001I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR07C0001C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6524338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0001(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Publication of FR07C0001I1 publication Critical patent/FR07C0001I1/fr
Application granted granted Critical
Publication of FR07C0001I2 publication Critical patent/FR07C0001I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
FR07C0001C 1994-07-20 2007-01-10 Active FR07C0001I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4426709A DE4426709A1 (de) 1994-07-20 1994-07-20 Steroidale Sexualhormone enthaltende feste Arzneiformen
PCT/EP1995/002656 WO1996002277A1 (de) 1994-07-20 1995-07-10 Feste arzneiformen, enthaltend clathrate von steroidalen sexualhormonen

Publications (2)

Publication Number Publication Date
FR07C0001I1 FR07C0001I1 (nl) 2007-03-09
FR07C0001I2 true FR07C0001I2 (nl) 2009-01-02

Family

ID=6524338

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0001C Active FR07C0001I2 (nl) 1994-07-20 2007-01-10

Country Status (11)

Country Link
US (1) US5798338A (nl)
EP (1) EP0771217B1 (nl)
JP (1) JPH10502912A (nl)
AT (1) ATE263578T1 (nl)
CA (1) CA2194979C (nl)
DE (4) DE4426709A1 (nl)
DK (1) DK0771217T3 (nl)
ES (1) ES2218561T3 (nl)
FR (1) FR07C0001I2 (nl)
PT (1) PT771217E (nl)
WO (1) WO1996002277A1 (nl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
AU2002222387A1 (en) * 2000-12-20 2002-07-01 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
US20070287684A1 (en) * 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP2249803A2 (en) * 2008-02-13 2010-11-17 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
MX2010008945A (es) * 2008-02-13 2010-09-07 Bayer Schering Pharma Ag Sistema de administracion de drogas con efecto estabilizante.
CA2725578A1 (en) * 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CN102985076A (zh) 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的低剂量的固体口服剂型
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
CN101869113B (zh) * 2010-06-17 2013-09-04 中国农业科学院植物保护研究所 一种鼠类不育剂的环糊精包合物及其制备方法
ES2784497T3 (es) 2010-09-16 2020-09-28 Shimoda Biotech Pty Ltd Composiciones de fulvestrant y métodos de uso
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
WO2013172969A1 (en) 2012-05-15 2013-11-21 The Uab Research Foundation Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
CA3079303A1 (en) 2017-10-16 2019-04-25 Faes Farma, S.A. Aqueous compositions comprising bilastine and mometasone
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
CN114225050B (zh) * 2022-01-29 2022-12-13 国家卫生健康委科学技术研究所 炔雌醇环糊精复合物的制备及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106698A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones

Also Published As

Publication number Publication date
JPH10502912A (ja) 1998-03-17
EP0771217B1 (de) 2004-04-07
CA2194979A1 (en) 1996-02-01
WO1996002277A1 (de) 1996-02-01
FR07C0001I1 (nl) 2007-03-09
DE59510887D1 (de) 2004-05-13
ES2218561T3 (es) 2004-11-16
ATE263578T1 (de) 2004-04-15
DK0771217T3 (da) 2004-08-02
EP0771217A1 (de) 1997-05-07
CA2194979C (en) 2009-01-06
DE4426709A1 (de) 1996-01-25
US5798338A (en) 1998-08-25
DE122007000013I1 (nl) 2007-04-26
PT771217E (pt) 2004-08-31
DE122007000011I1 (de) 2007-05-10

Similar Documents

Publication Publication Date Title
BR9508234A (nl)
IN183261B (nl)
EP0666525A3 (nl)
EP0671407A3 (nl)
EP0669187A3 (nl)
EP0666470A3 (nl)
EP0667627A3 (nl)
DK0685247T3 (nl)
BY1704C1 (nl)
IN180943B (nl)
ECSMU940030U (nl)
EP0662420A3 (nl)
IN182818B (nl)
ECSMU940033U (nl)
BRPI9401073A2 (nl)
CU22453A3 (nl)
CU22450A3 (nl)
ECSDI940181S (nl)
ECSDI940182S (nl)
ECSDI940184S (nl)
EP0662757A3 (nl)
EP0666636A3 (nl)
CN3028493S (nl)
EP0662609A3 (nl)
CN3027481S (nl)